OGOshmita Golam

Oshmita Golam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oshmita Golam has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey

    by Kimberly S Lakin, Antonia Valenzuela, John D Pauling, Deanna P Jannat-Khah, Kelsey Gripp, Oshmita Golam, Robyn T Domsic, Robert F Spiera, Jessica K Gordon

    Objectives: To evaluate contemporary global treatment of diffuse cutaneous systemic sclerosis (dcSSc) skin by SSc specialists. Methods: An anonymous survey was distributed via the Scleroderma Clinical Trials Consortium, European Scleroderma Trials and Research Group (EUSTAR), and Collaborative National Quality and Efficacy Registry (CONQUER) distribution lists between June–September 2025. The survey comprised four sections: Demographics, Treatment of dcSSc Skin, Impact of Recent Guidelines, and Clinical Trials. Results: Responses included 103 physicians (93 completed): 43% North America, 31% Europe, 15% South America, and 12% elsewhere. The majority practice within an SSc centre (80%) and participate in clinical trials (84%). Mycophenolate mofetil (MMF) was preferred first-line treatment (71%) for dcSSc without ILD, rising to 92% for dcSSc with mild/non-progressive ILD. For active skin involvement despite MMF, trial referral was preferred as next step irrespective of ILD (59% without ILD and 58% with ILD). Treatment preferences have evolved, with 40% increasing MMF use and 47% decreasing methotrexate use, over previous 2–3 years. Biologic use has increased, with 56% and 37% reporting increasing rituximab and tocilizumab use, respectively. For dcSSc without ILD, 85% have prescribed rituximab, and 65% have prescribed tocilizumab. Biologic availability has impacted trial enrolment (73% agreement). Treatment decision-making for dcSSc skin involvement has been materially influenced by recent BSR and/or EULAR guidelines (43% agreement). Conclusion: MMF is preferred first-line for dcSSc. In absence of compelling scientific justification for combination or step-up immunomodulatory approaches, trial referral is currently the preferred next treatment option. Biologic use is increasing which impacts trial enrolment.

  • Open Access

    Hippocampal representations of partner and novel individuals in monogamous California mice during pair bond formation

    by Kimberly Hernandez-Palacios, Oshmita Golam, Steven A. Siegelbaum, Andres Bendesky

    The hippocampal CA2 region is critical for social novelty recognition memory—the discrimination of whether a conspecific is novel or familiar. However, its role in forming a memory of a pair-bonded mate is unknown. To examine how social memories of pair-bonded individuals are encoded, we sought to understand if CA2 and the neighboring CA1 region participate in the memorization and recognition of a pair-bonded mate in monogamous Peromyscus californicus (California mice). Here, we report that CA2 and CA1 show distinct changes in social encoding of an opposite sex conspecific following pair-bonding. Using multi-channel silicon probes, we recorded single units from CA2 and CA1 in freely behaving male mice before and after pair bond formation during interactions with novel and partner females. We found that the strength of CA2 representations of a novel female mouse weakened after pair bond formation, indicating that CA2 may be preferentially important for novelty detection. In contrast, CA1 demonstrated an increase in the strength of encoding a female partner after pair-bond formation, suggesting that CA1 may encode partner memory. These findings indicate that pair bonding shifts the discrimination of social information from CA2 to CA1.